MEI Pharma has announced a rebranding to Lite Strategy, adopting Litecoin as the primary treasury asset and inviting Charlie Lee to guide the new approach.
MEI Pharma Rebranded to Lite Strategy
Lite Strategy Inc. revealed its new corporate direction, marking a significant shift from its biotech focus. The Nasdaq ticker will change to LITS on September 11, 2025.
Choosing Litecoin as the Main Asset
Litecoin (LTC) has become the first asset chosen by a U.S.-listed company for corporate reserves. Charlie Lee, the creator of Litecoin, will join the board, underscoring confidence in LTC's infrastructure. The conversion of over $100 million indicates a strong commitment to this new treasury strategy.
Market Impact and Potential Consequences
As of September 10, 2025, Litecoin trades at $115.07 with a market cap of $8.78 billion. Recent price volatility includes a 2.75% gain over 24 hours. This shift could herald further corporate adoption of cryptocurrencies, with implications for LTC's valuation and market stability.
MEI Pharma's transition to Litecoin as a primary corporate treasury asset marks a significant milestone in cryptocurrency adoption, potentially creating new opportunities for LTC and other assets.
